The COVID-19 pandemic and new clinical trial activations

• Published in: Current controlled trials in cardiovascular medicine Vol. 22; no. 1; p. 260
• Main Authors: Unger, Joseph M, Xiao, Hong
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08-04-2021; BioMed Central; BMC
• Subjects: Cancer clinical trials; Cardiovascular clinical trials; Clinical trials; Clinical Trials as Topic - statistics & numerical data; ClinicalTrials.gov; Coronaviruses; COVID-19; Disease; Epidemics; Humans; Influence; Medical research; Medicine, Experimental; Mental health; Mental health clinical trials; Observational Studies as Topic; Oncology; Pandemics; Retrospective Studies; Statistics; United States; United States > US; COVID-19; ClinicalTrials.gov; Mental health clinical trials; Cancer clinical trials; Cardiovascular clinical trials
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-021-05219-3

The COVID-19 pandemic has caused severe disruptions in care for many patients. A key question is whether the landscape of clinical research has also changed.
In a retrospective cohort study, we examined the association of the COVID-19 outbreak with new clinical trial activations. Trial data for all interventional and observational oncology, cardiovascular, and mental health studies from January 2015 through September 2020 were obtained from ClinicalTrials.gov . An interrupted time-series analysis with Poisson regression was used.
We examined 62,252 trial activations. During the initial COVID-19 outbreak (February 2020 through May 2020), model-estimated monthly trial activations for US-based studies were only 57% of the expected estimate had the pandemic not occurred (relative risk = 0.57, 95% CI 0.52 to 0.61, p < .001). For non-US-based studies, the impact of the pandemic was less dramatic (relative risk = 0.77, 95% CI 0.73 to 0.82, p < .001), resulting in an overall 27% reduction in the relative risk of new trial activations for US-based trials compared to non-US-based trials (relative risk ratio = 0.73, 95% CI 0.67 to 0.81, p < .001). Although a rebound occurred in the initial reopening phase (June 2020 through September 2020), the rebound was weaker for US-based studies compared to non-US-based studies (relative risk ratio = 0.87, 95% CI 0.80 to 0.95, p < .001).
These findings are consistent with the disproportionate burden of COVID-19 diagnoses and deaths during the initial phase of the pandemic in the USA. Reduced activation of cancer clinical trials will likely slow the pace of clinical research and new drug discovery, with long-term negative consequences for cancer patients. An important question is whether the renewed outbreak period of winter 2020/2021 will have a similarly negative impact on the initiation of new clinical research studies for non-COVID-19 diseases.